G2295
格列美脲
≥98% (HPLC), insulin secretagogue, solid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C24H34N4O5S
化学文摘社编号:
分子量:
490.62
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
格列美脲, ≥98% (HPLC), solid
SMILES string
CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O
InChI
1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
InChI key
WIGIZIANZCJQQY-RUCARUNLSA-N
assay
≥98% (HPLC)
form
solid
color
white
mp
212.2-214.5 °C
solubility
DMSO: >10 mg/mL
originator
Sanofi Aventis
storage temp.
room temp
Quality Level
Gene Information
human ... ABCC8(6833), KCNJ1(3758), KCNJ11(3767)
正在寻找类似产品? 访问 产品对比指南
相关类别
Application
格列美脲已被用于：
- 作为一种降糖药物用于测试其在人脐静脉细胞（HUVEC）中的抗糖尿病功能
- 在乳腺癌MDA-MB-231细胞中作为磺酰脲类ATP敏感型钾通道（KATP）抑制剂
- 在新生儿胰岛样细胞簇（NICC）的葡萄糖刺激胰岛素分泌（GSIS）测定中检测其对胰岛素分泌的影响
格列美脲目前用于治疗 2 型糖尿病。
Biochem/physiol Actions
心脏 KATP 通道的强力阻断剂。
格列美脲可通过刺激胰腺β细胞分泌胰岛素激素来降低血糖水平。它可与与β细胞相关的一种65-kD蛋白发生相互作用。
格列美脲是一种有效的心肌梗死 KATP 通道阻断剂，被吡那地尔激活，IC50 值为 6.8 nM。
Features and Benefits
该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
General description
格列美脲属于生物制药II类二代磺酰脲类药物。
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
Vladimer Darsalia et al.
Diabetes, 62(4), 1289-1296 (2012-12-05)
Type 2 diabetes is a strong risk factor for stroke. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes. The aim of this study was to determine the potential antistroke efficacy of linagliptin in type
Mitsuyoshi Takahara et al.
Endocrine journal, 59(12), 1131-1136 (2012-08-02)
We retrospectively investigated the effect of adding dipeptidyl peptidase-4 (DPP-4) inhibitor and tapering sulfonylurea on blood glucose fluctuation in Asian patients with type 2 diabetes mellitus under basal-supported oral therapy (BOT). We recruited twenty-two consecutive Japanese patients with type 2
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
William T Cefalu et al.
Lancet (London, England), 382(9896), 941-950 (2013-07-16)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持